For Hepatitis C Medicine, daclatasvir
Cadila Healthcare announced that Zydus Cadila has signed a non-exclusive, royalty free agreement with The Medicines Patent Pool (MPP) for the generic production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral (DAA) that is proven to help cure multiple genotypes of the Hepatitis C Virus (HCV). The agreement sub-licenses Zydus to produce and sell declatasvir in 112 low and middle income countries.Powered by Capital Market - Live News
